The first vaccine tested in the United States, developed at the National Institutes of Health and modern inc., stimulated the immune system of volunteers just as scientists had hoped. Phase 1 stages of the mRNA-1273 vaccine were published on Tuesday. Around July 27, a new phase will begin: a study of 30,000 people to test whether vaccines are actually strong enough to protect people from coronavirus.
“No matter how you see it, this is good news,” Dr. Anthony Fauci, the country’s leading infectious disease expert, told the Associated Press.
The experimental vaccine, developed by Fauci’s colleagues at the National Institutes of Health (NIH) and Modern Inc., will begin its most important phase around July 27: A study of 30,000 people to test whether vaccines are really strong enough to protect people from coronavirus.
But on Tuesday, researchers reported findings from the first 45 volunteers who were inoculated in March. The vaccine provided the expected immune boost.
Volunteers developed what is known as neutralizing antibodies in the bloodstream (key molecules to block infections) at levels comparable to those found in people who survived COVID-19, the research team reported in the New England Journal of Medicine.
There is no guarantee, but the government expects to have results by the end of the year, which would be a record speed to develop a vaccine.